Loading...
NASDAQ: HOWL
Werewolf Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$37.87M
52w High
$2.38
52w Low
$0.53
P/E
-0.49
Volume
178.91K
Outstanding Shares
48.54M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -27.76%Revenue (TTM): -100%FCF (TTM): -35.84%
What changed
The stock fell 27.76% over the last year. Revenue declined 100% over the trailing twelve months. Free cash flow declined 35.84% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Revenue declined 100% — this read reverses if that trend stabilizes. Free cash flow fell 35.84% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
CEODaniel J. Hicklin
SectorHealthcare
IndustryBiotechnology
Employees46
IPO dateApr 30, 2021
Valuation
Forward P/E—
EV/EBITDA0.15
Enterprise value-$9.78M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%▼95.87%vs FY2023
Operating margin0%▼1822.36%vs FY2023
ROE-96.08%▼186.37%vs FY2023
Analyst consensus
RatingBuy
Target price$1.00▲28.17%
9
Buy
0
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 31, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
-$0.40
-$0.44
Q3FY25
ActualEst.
-$0.40
-$0.50
Q4FY25
ActualEst.
-$0.36
-$0.39
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
—
$375K
Q3FY25
ActualEst.
—
—
Q4FY25
ActualEst.
—
—
Q1FY26
Next Est.
—